- Ownership
-
KALA BIO, Inc. Executive Compensation
* In original currency USD
Loading Data
|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total Amount |
|---|---|---|---|---|---|---|---|---|
| Tuesday, December 30th, 2025 | 2023 | Mark Iwicki Former Chief Executive Officer | 709,394 | 297,945 | 4,615,426 | 0 | 6,097 | 8,342,714 |
| Tuesday, December 30th, 2025 | 2024 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 520,000 | 163,800 | 45,500 | 0 | 19,844 | 920,687 |
| Tuesday, December 30th, 2025 | 2023 | Todd Bazemore Former Interim Chief Executive Officer, Former President and Chief Operating Officer | 535,600 | 187,460 | 1,378,219 | 0 | 10,520 | 2,943,656 |
| Tuesday, December 30th, 2025 | 2024 | Mark Iwicki Former Chief Executive Officer | 709,394 | 297,945 | 100,100 | 0 | 6,120 | 1,491,187 |
| Tuesday, December 30th, 2025 | 2023 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 520,000 | 163,800 | 1,370,495 | 0 | 25,685 | 2,923,073 |
| Tuesday, December 30th, 2025 | 2024 | Todd Bazemore Former Interim Chief Executive Officer, Former President and Chief Operating Officer | 535,600 | 187,460 | 45,500 | 0 | 9,447 | 949,550 |
| Monday, April 29th, 2024 | 2022 | Todd Bazemore President and Chief Operating Officer | 515,000 | 257,500 | 0 | 0 | 10,540 | 1,025,817 |
| Monday, April 29th, 2024 | 2022 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 500,000 | 225,000 | 0 | 0 | 25,912 | 993,689 |
| Monday, April 29th, 2024 | 2023 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 520,000 | 163,800 | 1,370,495 | 0 | 25,685 | 2,923,073 |
| Monday, April 29th, 2024 | 2022 | Mark Iwicki Chief Executive Officer | 682,110 | 409,266 | 0 | 0 | 6,120 | 1,868,299 |
| Monday, April 29th, 2024 | 2023 | Mark Iwicki Chief Executive Officer | 709,394 | 297,945 | 4,615,426 | 0 | 6,097 | 8,342,714 |
| Monday, April 29th, 2024 | 2023 | Todd Bazemore President and Chief Operating Officer | 535,600 | 187,460 | 1,378,219 | 0 | 10,520 | 2,943,656 |
| Thursday, May 11th, 2023 | 2022 | Mark Iwicki Chief Executive Officer | 682,110 | 409,266 | 0 | 0 | 6,120 | 1,868,299 |
| Thursday, May 11th, 2023 | 2022 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 500,000 | 225,000 | 0 | 0 | 25,912 | 993,689 |
| Thursday, May 11th, 2023 | 2021 | Todd Bazemore President and Chief Operating Officer | 489,878 | 171,457 | 188,650 | 0 | 10,240 | 1,343,356 |
| Thursday, May 11th, 2023 | 2021 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 476,207 | 150,005 | 188,650 | 0 | 18,976 | 1,316,969 |
| Thursday, May 11th, 2023 | 2022 | Todd Bazemore President and Chief Operating Officer | 515,000 | 257,500 | 0 | 0 | 10,540 | 1,025,817 |
| Thursday, May 11th, 2023 | 2021 | Mark Iwicki Chief Executive Officer | 643,500 | 270,270 | 521,360 | 0 | 6,120 | 2,772,056 |
| Monday, March 13th, 2023 | 2021 | Todd Bazemore President and Chief Operating Officer | 489,878 | 171,457 | 188,650 | 0 | 10,240 | 1,343,356 |
| Monday, March 13th, 2023 | 2021 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 476,207 | 150,005 | 188,650 | 0 | 18,976 | 1,316,969 |
| Monday, March 13th, 2023 | 2022 | Todd Bazemore President and Chief Operating Officer | 515,000 | 257,500 | 0 | 0 | 10,540 | 1,025,817 |
| Monday, March 13th, 2023 | 2022 | Mark Iwicki Chief Executive Officer | 682,110 | 409,266 | 0 | 0 | 6,120 | 1,868,299 |
| Monday, March 13th, 2023 | 2021 | Mark Iwicki Chief Executive Officer | 643,500 | 270,270 | 521,360 | 0 | 6,120 | 2,772,056 |
| Monday, March 13th, 2023 | 2022 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 500,000 | 225,000 | 0 | 0 | 25,912 | 993,689 |
| Friday, April 29th, 2022 | 2021 | Kim Brazzell, Ph.D. Head of Research and Developemnt and Chief Medical Officer | 476,207 | 150,005 | 188,650 | 0 | 18,976 | 1,316,969 |
| Friday, April 29th, 2022 | 2020 | Todd Bazemore President and Chief Operating Officer | 455,700 | 273,420 | 1,170,000 | 0 | 10,419 | 2,228,316 |
| Friday, April 29th, 2022 | 2020 | Kim Brazzell, Ph.D. Head of Research and Developemnt and Chief Medical Officer | 455,700 | 373,420 | 1,170,000 | 0 | 19,155 | 2,336,604 |
| Friday, April 29th, 2022 | 2021 | Mark Iwicki Chief Executive Officer | 643,500 | 270,270 | 521,360 | 0 | 6,120 | 2,772,056 |
| Friday, April 29th, 2022 | 2020 | Mark Iwicki Chief Executive Officer | 585,500 | 676,500 | 2,665,962 | 0 | 4,719 | 4,901,760 |
| Friday, April 29th, 2022 | 2021 | Todd Bazemore President and Chief Operating Officer | 489,878 | 171,457 | 188,650 | 0 | 10,240 | 1,343,356 |
| Wednesday, April 28th, 2021 | 2019 | Kim Brazzell, Ph.D. Chief Medical Officer | 440,300 | 158,508 | 0 | 0 | 15,338 | 1,164,505 |
| Wednesday, April 28th, 2021 | 2020 | Kim Brazzell, Ph.D. Chief Medical Officer | 455,700 | 373,420 | 1,170,000 | 0 | 19,155 | 2,336,604 |
| Wednesday, April 28th, 2021 | 2019 | Mark Iwicki President and Chief Executive Officer | 563,500 | 304,290 | 0 | 0 | 3,353 | 2,556,167 |
| Wednesday, April 28th, 2021 | 2019 | Todd Bazemore Chief Operating Officer | 440,300 | 158,508 | 0 | 0 | 8,694 | 1,674,106 |
| Wednesday, April 28th, 2021 | 2020 | Todd Bazemore Chief Operating Officer | 455,700 | 273,420 | 1,170,000 | 0 | 10,419 | 2,228,316 |
| Wednesday, April 28th, 2021 | 2020 | Mark Iwicki President and Chief Executive Officer | 585,500 | 676,500 | 2,665,962 | 0 | 4,719 | 4,901,760 |
| Wednesday, April 29th, 2020 | 2018 | Eric L. Trachtenberg General Counsel and Chief Compliance Officer | 288,750 | 184,800 | 0 | 0 | 133,691 | 2,416,706 |
| Wednesday, April 29th, 2020 | 2018 | Todd Bazemore Chief Operating Officer | 405,000 | 194,400 | 0 | 0 | 12,950 | 845,458 |
| Wednesday, April 29th, 2020 | 2019 | Todd Bazemore Chief Operating Officer | 440,300 | 158,508 | 0 | 0 | 8,694 | 1,674,106 |
| Wednesday, April 29th, 2020 | 2019 | Eric L. Trachtenberg General Counsel and Chief Compliance Officer | 396,600 | 142,776 | 0 | 0 | 107,186 | 1,495,347 |
| Wednesday, April 29th, 2020 | 2019 | Mark Iwicki Chief Executive Officer | 563,500 | 304,290 | 0 | 0 | 3,353 | 2,556,167 |
| Wednesday, April 29th, 2020 | 2018 | Mark Iwicki Chief Executive Officer | 534,681 | 385,000 | 0 | 0 | 7,709 | 3,072,185 |
| Friday, April 12th, 2019 | 2017 | Kim Brazzell, M.D. Chief Medical Officer | 384,211 | 205,500 | 0 | 0 | 14,580 | 1,184,024 |
| Friday, April 12th, 2019 | 2018 | Kim Brazzell, M.D. Chief Medical Officer | 425,386 | 204,200 | 0 | 0 | 14,312 | 1,296,545 |
| Friday, April 12th, 2019 | 2017 | Mark Iwicki Chief Executive Officer | 500,588 | 387,450 | 0 | 0 | 1,863 | 1,857,577 |
| Friday, April 12th, 2019 | 2018 | Mark Iwicki Chief Executive Officer | 534,681 | 385,000 | 0 | 0 | 7,709 | 3,072,185 |
| Friday, April 12th, 2019 | 2018 | Eric L. Trachtenberg General Counsel and Chief Compliance Officer | 288,750 | 184,800 | 0 | 0 | 133,691 | 2,416,706 |
| Wednesday, April 25th, 2018 | 2017 | Todd Bazemore Chief Operating Officer | 46,731 | 190,000 | 0 | 0 | 971 | 2,997,475 |
| Wednesday, April 25th, 2018 | 2016 | Kim Brazzell, M.D. Chief Medical Officer | 340,973 | 141,750 | 0 | 0 | 1,710 | 859,488 |
| Wednesday, April 25th, 2018 | 2017 | Kim Brazzell, M.D. Chief Medical Officer | 384,211 | 205,500 | 0 | 0 | 2,119 | 966,063 |
| Wednesday, April 25th, 2018 | 2016 | Mark Iwicki Chief Executive Officer | 472,738 | 254,300 | 0 | 0 | 1,298 | 2,261,867 |
| Wednesday, April 25th, 2018 | 2017 | Mark Iwicki Chief Executive Officer | 500,588 | 387,450 | 0 | 0 | 1,863 | 1,470,127 |
